<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261637</url>
  </required_header>
  <id_info>
    <org_study_id>IWK-4518-2009</org_study_id>
    <secondary_id>IWK REB 4518</secondary_id>
    <nct_id>NCT01261637</nct_id>
  </id_info>
  <brief_title>Abdominal Wall Local Anesthesia to Maximize Postoperative Pain Control After Cesarean Delivery</brief_title>
  <official_title>Ultrasound Guided 0.25% Ropivacaine Transversus Abdominis Plane Block in Addition to Intrathecal Morphine and Multimodal Analgesia for the Management of Postoperative Pain Among Women Undergoing Cesarean Delivery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IWK Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to determine if women undergoing cesarean delivery with spinal
      anesthesia and routine pain management who also have an additional ultrasound guided
      transversus abdominis plane (TAP)block using ropivacaine have better pain relief and a better
      quality of recovery than women who don't have the additional TAP block. Maximizing pain
      relief using ultrasound guided TAP blocks in addition to neuraxial opioids, NSAIDs, and
      acetaminophen may improve acute pain outcomes, reduce adverse side effects, and potentially
      reduce chronic pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be postoperative pain, measured by an NRS, the quality of recovery score (QoR) and a Self Assessment Diary in the first 24h postoperative period.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS / QoR - 48 hour Opioid Consumption Side effects - nausea, sedation</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAP block success rates and duration of block effect will be assessed using a patient diary completed every 2 hours while the patient is awake.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistant pain outcomes will be assessed at 30 days and 6 months using 5-minute SF-36 health survey.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>0.25% Ropivicaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25% ropivicaine (maximum 1.5mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20ml saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>20ml saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivicaine</intervention_name>
    <description>0.25% ropivicaine (maximum 1.5mg/kg)</description>
    <arm_group_label>0.25% Ropivicaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-emergent CD with planned spinal anesthesia

          -  American Society of Anesthesia physical status class I &amp; II

          -  Age ≥ 18 years

          -  Term gestational age (≥ 37 weeks)

          -  English-speaking

        Exclusion Criteria:

          -  Morbid Obesity (BMI³ 45 kg/m2)

          -  Laboring women

          -  Emergency CD

          -  Severe maternal cardiac disease

          -  Subjects with significant obstetric co-morbidities

          -  Failed spinal anesthesia

          -  Patient enrollment in another study involving medication within 30 days of CD

          -  Any other condition which may impair ability to cooperate with data collection

          -  Height less than 152 cm (5'0&quot;)

          -  Fetal anomalies or intrauterine fetal death
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolores McKeen, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>IWK Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>May 22, 2013</last_update_submitted>
  <last_update_submitted_qc>May 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IWK Health Centre</investigator_affiliation>
    <investigator_full_name>Ronald George</investigator_full_name>
    <investigator_title>Primary Investigator, MD, FRCPC, Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>cesarean, pain, transversus abdominus plane block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

